Antiviral activity of the interferon-induced cellular protein BST-2/tetherin

AIDS Research and Human Retroviruses

Volumn 25, Issue 12, 2009, Pages 1197-1210

  Tokarev, Andrey ^a   Skasko, Mark ^a   Fitzpatrick, Kathleen ^a   Guatelli, John ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BONE MARROW STROMAL ANTIGEN 2; INTERFERON; MEMBRANE PROTEIN; NEF PROTEIN; TETHERIN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN; VIRUS PROTEIN; VPU PROTEIN; VPU PROTEIN INHIBITOR;

AMINO TERMINAL SEQUENCE; ANTIVIRAL ACTIVITY; ARENAVIRUS; CARBOXY TERMINAL SEQUENCE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG TARGETING; ENDOSOME; FILOVIRUS; HERPES VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2; MOLECULAR EVOLUTION; NEGATIVE FEEDBACK; NONHUMAN; ORTHOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; RETROVIRUS; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; SPECIES; VIRION; VIRUS IMMUNITY; VIRUS TRANSMISSION;

ANIMALS; ANTIGENS, CD; DENDRITIC CELLS; GENE EXPRESSION REGULATION; HIV INFECTIONS; HIV-1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; INTERFERONS; MEMBRANE GLYCOPROTEINS; UBIQUITIN-PROTEIN LIGASE COMPLEXES; VIRAL REGULATORY AND ACCESSORY PROTEINS;

EID: 73149087722     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0253     Document Type: Review

References (77)

1. Strebel K, Klimkait T, and Martin MA: A novel gene of HIV- 1, vpu, and its 16-kilodalton product. Science 1988;241:1221-1223.
2. Cohen EA, Terwilliger EF, Sodroski JG, and Haseltine WA: Identification of a protein encoded by the vpu gene of HIV- 1. Nature 1988;334:532-534.
3. Klimkait T, Strebel K, Hoggan MD, Martin MA, and Orenstein JM: The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release. J Virol 1990;64(2):621-629.
4. Sakai H, Tokunaga K, Kawamura M, and Adachi A: Function of human immunodeficiency virus type 1 Vpu protein in various cell types. J Gen Virol 1995;76( Pt 11): 2717-2722.
5. Yasuda Y, Miyake S, Kato S, et al.: Interferon-alpha treatment leads to accumulation of virus particles on the surface of cells persistently infected with the human immunodeficiency virus type 1. J Acquir Immune Defic Syndr 1990;3(11): 1046-1051. (Pubitemid 20373632)
6. Dianzani F, Castilletti C, Gentile M, et al.: Effects of IFN alpha on late stages of HIV-1 replication cycle. Biochimie 1998;80(8-9):745-754.
7. Gottlinger HG, Dorfman T, Cohen EA, and Haseltine WA: Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses. Proc Natl Acad Sci USA 1993;90(15):7381-7385.
8. Varthakavi V, Smith RM, Bour SP, Strebel K, and Spearman P: Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production. Proc Natl Acad Sci USA 2003;100(25):15154-15159.
9. Neil SJ, Eastman SW, Jouvenet N, and Bieniasz PD: HIV-1 Vpu promotes release and prevents endocytosis of nascent retrovirus particles from the plasma membrane. PLoS Pathog 2006;2(5):e39.
10. Neil SJ, Sandrin V, Sundquist WI, and Bieniasz PD: An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein. Cell Host Microbe 2007;2(3):193-203.
11. Bartee E, McCormack A, and Fruh K: Quantitative membrane proteomics reveals new cellular targets of viral immune modulators. PLoS Pathog 2006;2(10):e107.
12. Margottin F, Bour SP, Durand H, et al.: A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol Cell 1998;1(4):565-574.
13. Blasius AL, Giurisato E, Cella M, et al.: Bone marrow stromal cell antigen 2 is a specific marker of type I IFN-producing cells in the naive mouse, but a promiscuous cell surface antigen following IFN stimulation. J Immunol 2006;177(5): 3260-3265.
14. Vidal-Laliena M, Romero X, March S, et al.: Characterization of antibodies submitted to the B cell section of the 8th Human Leukocyte Differentiation Antigens Workshop by flow cytometry and immunohistochemistry. Cell Immunol 2005;236(1-2):6-16.
15. Kupzig S, Korolchuk V, Rollason R, et al.: Bst-2=HM1.24 is a raft-associated apical membrane protein with an unusual topology. Traffic 2003;4(10):694-709.
16. Van Damme N, Goff D, Katsura C, et al.: The interferoninduced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 2008;3(4):245-252.
17. Neil SJ, Zang T, and Bieniasz PD: Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008; 451(7177):425-430.
18. Ohtomo T, Sugamata Y, Ozaki Y, et al.: Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. Biochem Biophys Res Commun 1999;258(3):583-591.
19. Rollason R, Korolchuk V, Hamilton C, Schu P, and Banting G: Clathrin-mediated endocytosis of a lipid-raft-associated protein is mediated through a dual tyrosine motif. J Cell Sci 2007;120(Pt 21):3850-3858.
20. Masuyama N, Kuronita T, Tanaka R, et al.: HM1.24 is internalized from lipid rafts by clathrin-mediated endocytosis through interaction with alpha-adaptin. J Biol Chem 2009; 284(23):15927-15941.
21. Mansouri M, Viswanathan K, Douglas JL, et al.: Molecular mechanism of BST2=tetherin downregulation by K5=MIR2 of Kaposi's sarcoma-associated herpesvirus. J Virol 2009; 83(19):9672-9681.
22. Jia B, Serra-Moreno R, Neidermyer W, et al.: Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin=BST2. PLoS Pathog 2009;5(5):e1000429.
23. Zhang F, Wilson SJ, Landford WC, et al.: Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbe 2009;6(1):54-67.
24. Dube M, Roy BB, Guiot-Guillain P, et al.: Suppression of tetherin-restricting activity upon human immunodeficiency virus type 1 particle release correlates with localization of Vpu in the trans-Golgi network. J Virol 2009;83(9):4574-4590.
25. Aloia RC, Tian H, and Jensen FC: Lipid composition and fluidity of the human immunodeficiency virus envelope and host cell plasma membranes. Proc Natl Acad Sci USA 1993;90(11):5181-5185.
26. Nguyen DH and Hildreth JEK: Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts. J Virol 2000;74: 3264-3272.
27. Panchal RG, Ruthel G, Kenny TA, et al.: In vivo oligomerization and raft localization of Ebola virus protein VP40 during vesicular budding. Proc Natl Acad Sci USA 2003; 100(26):15936-15941.
28. Sakuma T, Noda T, Urata S, Kawaoka Y, and Yasuda J: Inhibition of Lassa and Marburg virus production by tetherin. J Virol 2009;83(5):2382-2385.
29. Andrew AJ, Miyagi E, Kao S, and Strebel K: The formation of cysteine-linked dimers of BST-2=tetherin is important for inhibition of HIV-1 virus release but not for sensitivity to Vpu. Retrovirology 2009;6(1):80.
30. Sakuma T, Sakurai A, and Yasuda J: Dimerization of tetherin is not essential for its antiviral activity against Lassa and Marburg viruses. PLoS One 2009;4(9):e6934.
31. Kaletsky RL, Francica JR, grawal-Gamse C, and Bates P: Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc Natl Acad Sci U S A 2009;106(8):2886-2891.
32. Sakuma T, Noda T, Urata S, Kawaoka Y, and Yasuda J: Inhibition of Lassa and Marburg virus production by tetherin. J Virol 2008;83(5):2382-2385.
33. Jouvenet N, Neil SJ, Zhadina M, et al.: Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. J Virol 2009;83(4):1837-1844.
34. Mitchell RS, Katsura C, Skasko MA, et al.: Vpu antagonizes BST-2-mediated restriction ofHIV-1 release via beta-TrCP and endo-lysosomal trafficking. PLoS Pathog 2009;5(5):e1000450.
35. Fitzpatrick K, SkaskoM, Deerinck T, et al.: Direct restriction of virus release and incorporation of the interferon-induced protein BST-2 into HIV-1 particles. PLoS Pathog 2009, in press.
36. Perez-Caballero D, Zang T, Ebrahimi A, et al.: Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell 2009;139:499-511.
37. Sato K, Yamamoto SP, Misawa N, et al.: Comparative study on the effect of human BST-2=tetherin on HIV-1 release in cells of various species. Retrovirology 2009;6:53.
38. Malim MH and Emerman M: HIV-1 accessory proteins- ensuring viral survival in a hostile environment. Cell Host Microbe 2008;3(6):388-398.
39. Stremlau M, Owens CM, Perron MJ, et al.: The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 2004;427(6977):848-853.
40. Yu X, Yu Y, Liu B, et al.: Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 2003;302(5647):1056-1060.
41. Mehle A, Strack B, Ancuta P, et al.: Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J Biol Chem 2004; 279(9):7792-7798.
42. Barry M and Fruh K: Viral modulators of cullin RING ubiquitin ligases: Culling the host defense. Sci STKE 2006; 2006(335):e21.
43. Le Tortorec A and Neil SJ: Antagonism and intracellular sequestration of human tetherin by the HIV-2 envelope glycoprotein. J Virol 2009;83:11966-11978.
44. Gupta RK, Mlcochova P, Pelchen-Matthews A, et al.: Simian immunodeficiency virus envelope glycoprotein counteracts tetherin=BST-2=CD317 by intracellular sequestration. Proc Natl Acad Sci USA 2009 epub.
45. Gupta RK, Hue S, Schaller T, et al.: Mutation of a single residue renders human tetherin resistant to HIV-1 Vpumediated depletion. PLoS Pathog 2009;5(5):e1000443.
46. Goffinet C, Allespach I, Homann S, et al.: HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. Cell Host Microbe 2009;5(3):285-297.
47. Varthakavi V, Smith RM, Martin KL, et al.: The pericentriolar recycling endosome plays a key role in Vpu-mediated enhancement of HIV-1 particle release. Traffic 2006;7(3):298-307.
48. Van Damme N and Guatelli J: HIV-1 Vpu inhibits accumulation of the envelope glycoprotein within clathrincoated, Gag-containing endosomes. Cell Microbiol 2007;10: 1040-1057.
49. Rong L, Zhang J, Lu J, et al.: The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu. J Virol 2009; 83(15):7536-7546.
50. Douglas JL, Viswanathan K, McCarroll MN, et al.: Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2=tetherin via a {beta}TrCP-dependent mechanism. J Virol 2009;83(16):7931-7947.
51. Mangeat B, Gers-Huber G, Lehmann M, et al.: HIV-1 Vpu neutralizes the antiviral factor tetherin=BST-2 by binding it and directing its beta-TrCP2-dependent degradation. PLoS Pathog 2009;5(9):e1000574.
52. Miyagi E, Andrew AJ, Kao S, and Strebel K: Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface downmodulation and intracellular depletion. Proc Natl Acad Sci USA 2009;106(8):2868-2873.
53. Lim E and Emerman M: Simian immunodeficiency virus from African green monkeys (SIVagm) does not antagonize endogenous levels of African green monkey tetherin=BST-2. J Virol 2009;83(22):11673-11681.
54. Iwabu Y, Fujita H, Kinomoto M, et al.: HIV-1 accessory protein Vpu internalizes cell-surface BST-2=tetherin through transmembrane interactions leading to lysosomes. J Biol Chem 2009 epub.
55. Bour S, Schubert U, Peden K, and Strebel K: The envelope glycoprotein of human immunodeficiency virus type 2 enhances viral particle release: A Vpu-like factor? J Virol 1996;70(2):820-829.
56. Abada P, Noble B, and Cannon PM: Functional domains within the human immunodeficiency virus type 2 envelope protein required to enhance virus production. J Virol 2005; 79(6):3627-3638.
57. Mettenleiter TC, Klupp BG, and Granzow H: Herpesvirus assembly: An update. Virus Res 2009;143(2):222-234.
58. McNatt MW, Zang T, Hatziioannou T, et al.: Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathog 2009;5(2): e1000300.
59. Schubert U, Bour S, Ferrer-Montiel AV, et al.: The two biological activities of human immunodeficiency virus type 1 Vpu protein involve two separable structural domains. J Virol 1996;70(2):809-819.
60. Gummuluru S, Kinsey CM, and Emerman M: An in vitro rapid-turnover assay for human immunodeficiency virus type 1 replication selects for cell-to-cell spread of virus. J Virol 2000;74(23):10882-10891.
61. Miyauchi K, Kim Y, Latinovic O, Morozov V, and Melikyan GB: HIV enters cells via endocytosis and dynamindependent fusion with endosomes. Cell 2009:137(3):433-444.
62. Miyakawa K, Ryo A, Murakami T, et al.: BCA2=Rabring7 promotes tetherin-dependent HIV-1 restriction. PLoS Pathog 2009, in press.
63. Schubert U, Ferrer-Montiel AV, Oblatt-Montal M, et al.: Identification of an ion channel activity of the Vpu transmembrane domain and its involvement in the regulation of virus release from HIV-1-infected cells. FEBS Lett 1996; 398(1):12-18.
64. Lopez CF, Montal M, Blasie JK, Klein ML, and Moore PB: Molecular dynamics investigation of membrane-bound bundles of the channel-forming transmembrane domain of viral protein U from the human immunodeficiency virus HIV-1. Biophys J 2002;83(3):1259-1267.
65. Park SH, De Angelis AA, Nevzorov AA, Wu CH, and Opella SJ: Three-dimensional structure of the transmembrane domain of Vpu from HIV-1 in aligned phospholipid bicelles. Biophys J 2006;91(8):3032-3042.
66. Montal M: Vpu matchmakers as a therapeutic strategy for HIV infection. PLoS Pathog 2009;5(5):e1000246.
67. Hsu K, Seharaseyon J, Dong P, Bour S, and Marban E: Mutual functional destruction of HIV-1 Vpu and host TASK- 1 channel. Mol Cell 2004;14(2):259-267.
68. Hatziioannou T, Ambrose Z, Chung NP et al.: A macaque model of HIV-1 infection. Proc Natl Acad Sci USA 2009;106(11):4425-4429.
69. Wong SK, Connole M, Sullivan JS, et al.: A New World primate deficient in tetherin-mediated restriction of human immunodeficiency virus type 1. J Virol 2009;83(17):8771-8780.
70. Barlow KL, Ajao AO, and Clewley JP: Characterization of a novel simian immunodeficiency virus (SIVmonNG1) genome sequence from a mona monkey (Cercopithecus mona). J Virol 2003;77(12):6879-6888.
71. Courgnaud V, Salemi M, Pourrut X, et al.: Characterization of a novel simian immunodeficiency virus with a vpu gene from greater spot-nosed monkeys (Cercopithecus nictitans) provides new insights into simian=human immunodeficiency virus phylogeny. J Virol 2002;76(16):8298-8309.
72. Dazza MC, Ekwalanga M, Nende M, et al.: Characterization of a novel vpu-harboring simian immunodeficiency virus from a Dent's Mona monkey (Cercopithecus mona denti). J Virol 2005;79(13):8560-8571.
73. Bailes E, Gao F, Bibollet-Ruche F, et al.: Hybrid origin of SIV in chimpanzees. Science 2003;300(5626):1713.
74. Stephens EB, McCormick C, Pacyniak E, et al.: Deletion of the vpu sequences prior to the Env in a simian-human immunodeficiency virus results in enhanced Env precursor synthesis but is less pathogenic for pig-tailed macaques. Virology 2002;293(2):252-261.
75. Bour S, Akari H, Miyagi E, and Strebel K: Naturally occurring amino acid substitutions in the HIV-2 ROD envelope glycoprotein regulate its ability to augment viral particle release. Virology 2003;309(1):85-98.
76. Cao W, Bover L, Cho M, et al.: Regulation of TLR7=9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction. J Exp Med 2009;206(7):1603-1614.
77. Karplus K, Karchin R, Draper J, et al.: Combining localstructure, fold-recognition, and new fold methods for protein structure prediction. Proteins 2003;53(Suppl 6):491-496.